<?xml version="1.0" ?>
<GlossaryTerm id="CDR0000045051">
  <TermName>apolizumab</TermName>
  <TermPronunciation>(a-puh-LIZ-yoo-mab)</TermPronunciation>
  <TermDefinition>
    <DefinitionText>A substance being studied in the treatment of hematologic (blood) cancers. Apolizumab binds to a protein called ID10, which is found on the surface of some types of immune cells and cancer cells. It may help the immune system kill cancer cells.  It is a type of monoclonal antibody.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </TermDefinition>
  <MediaLink ref="CDR0000706295" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;apolizumab&quot;" language="en" id="_3"/>
  <MediaLink ref="CDR0000706294" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;apolizumab&quot;" language="es" id="_4"/>
  <SpanishTermName>apolizumab</SpanishTermName>
  <SpanishTermDefinition>
    <DefinitionText>Sustancia en estudio para el tratamiento de cánceres hematológicos (de la sangre). El apolizumab se une a una proteína que se llama ID10, que se encuentra en la superficie de algunos tipos de células inmunitarias y células cancerosas. Podría ayudar al sistema inmunitario a destruir células cancerosas. Es un tipo de anticuerpo monoclonal.</DefinitionText>
    <Dictionary>Cancer.gov</Dictionary>
    <Audience>Patient</Audience>
  </SpanishTermDefinition>
  <DateLastModified>2011-01-12</DateLastModified>
</GlossaryTerm>
